Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.28)
# 386
Out of 5,182 analysts
95
Total ratings
54.41%
Success rate
16.09%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UPB Upstream Bio | Downgrades: In-Line | $40 → $15 | $9.50 | +57.89% | 2 | Mar 27, 2026 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $30 → $45 | $33.33 | +35.01% | 3 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $100 → $125 | $73.15 | +70.88% | 4 | Feb 25, 2026 | |
| ACLX Arcellx | Downgrades: In-Line | $115 | $114.77 | +0.20% | 2 | Feb 24, 2026 | |
| VIR Vir Biotechnology | Maintains: Outperform | $12 → $18 | $9.06 | +98.68% | 2 | Feb 24, 2026 | |
| MRNA Moderna | Maintains: In-Line | $28 → $35 | $49.20 | -28.86% | 7 | Feb 17, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $750 → $875 | $761.85 | +14.85% | 6 | Jan 22, 2026 | |
| IMNM Immunome | Maintains: Outperform | $18 → $40 | $21.84 | +83.15% | 2 | Dec 16, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $55 | $21.46 | +156.29% | 1 | Nov 26, 2025 | |
| BEAM Beam Therapeutics | Initiates: Outperform | $35 | $24.66 | +41.93% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $8.89 | +181.21% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $80 | $66.73 | +19.89% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $19.38 | +75.44% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $56.85 | -3.25% | 1 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $185 | $131.60 | +40.58% | 2 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $110 → $125 | $91.18 | +37.09% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $105 | $55.50 | +89.19% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $22.45 | +291.98% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $177.34 | +55.63% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $3.20 | +993.75% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $347.94 | -33.32% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $95.93 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $139.71 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $34.84 | -39.72% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $6.90 | +233.33% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.59 | +528.93% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $11.87 | - | 5 | Feb 14, 2018 |
Upstream Bio
Mar 27, 2026
Downgrades: In-Line
Price Target: $40 → $15
Current: $9.50
Upside: +57.89%
Edgewise Therapeutics
Feb 27, 2026
Maintains: Outperform
Price Target: $30 → $45
Current: $33.33
Upside: +35.01%
BridgeBio Pharma
Feb 25, 2026
Maintains: Outperform
Price Target: $100 → $125
Current: $73.15
Upside: +70.88%
Arcellx
Feb 24, 2026
Downgrades: In-Line
Price Target: $115
Current: $114.77
Upside: +0.20%
Vir Biotechnology
Feb 24, 2026
Maintains: Outperform
Price Target: $12 → $18
Current: $9.06
Upside: +98.68%
Moderna
Feb 17, 2026
Maintains: In-Line
Price Target: $28 → $35
Current: $49.20
Upside: -28.86%
Regeneron Pharmaceuticals
Jan 22, 2026
Maintains: Outperform
Price Target: $750 → $875
Current: $761.85
Upside: +14.85%
Immunome
Dec 16, 2025
Maintains: Outperform
Price Target: $18 → $40
Current: $21.84
Upside: +83.15%
Zenas BioPharma
Nov 26, 2025
Initiates: Outperform
Price Target: $55
Current: $21.46
Upside: +156.29%
Beam Therapeutics
Nov 24, 2025
Initiates: Outperform
Price Target: $35
Current: $24.66
Upside: +41.93%
Nov 20, 2025
Initiates: Outperform
Price Target: $25
Current: $8.89
Upside: +181.21%
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $66.73
Upside: +19.89%
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $19.38
Upside: +75.44%
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $56.85
Upside: -3.25%
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $131.60
Upside: +40.58%
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $91.18
Upside: +37.09%
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $55.50
Upside: +89.19%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $22.45
Upside: +291.98%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $177.34
Upside: +55.63%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $3.20
Upside: +993.75%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $347.94
Upside: -33.32%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $95.93
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $139.71
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $34.84
Upside: -39.72%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $6.90
Upside: +233.33%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.59
Upside: +528.93%
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $11.87
Upside: -